Prosecution Insights
Last updated: November 12, 2026
Application No. 18/711,570

COMPOUNDS FOR USE IN TREATING GASTRIC CANCER

Final Rejection §103
Filed
May 17, 2024
Priority
Nov 17, 2021 — provisional 63/280,540 +1 more
Examiner
GONZALEZ, LUISALBERTO
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BPGbio, Inc.
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
96 granted / 164 resolved
-1.5% vs TC avg
Strong +48% interview lift
Without
With
+48.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
63 currently pending
Career history
234
Total Applications
across all art units

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Information Disclosure Statement The information disclosure statement received 09/14/2026 has been considered. Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-2 is/are rejected under 35 U.S.C. 103 as being unpatentable over Vishnudas (US11,091,447, priority to 01/03/2020) in view of NCI (NIH National Cancer Institute, published 2016, url=https://www.cancer.gov/types/metastatic-cancer, accessed 05/07/2026). KSR Rationales The MPEP in section 2143, subsection I gives examples of Rationales for supporting a conclusion of obvious. These rationales are non-exhaustive and include (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Claims 1-2 are drawn to methods of treating gastric cancer comprising administering a compound (structure shown below). Claim 2 specifies metastatic gastric cancer. Vishnudas in col. 79 teaches the synthesis of compound 126, shown below. PNG media_image1.png 302 762 media_image1.png Greyscale Vishnudas in col. 8, l. 12-35 contemplates treating cancers, including gastric cancer (gastrointestinal cancer), via administering compounds and/or compositions comprising said compound of its invention. Vishnudas does not contemplate metastatic gastric cancer. This is addressed by the combination of NCI. NCI in sec. What is Metastatic Cancer? States “Metastatic cancer has the same name as the primary cancer. For example, breast cancer that spreads to the lung is called metastatic breast cancer, not lung cancer. It is treated as stage IV breast cancer, not lung cancer.” This teaching indicates that treatment for non-metastatic cancers would be the same as treatment for metastatic cancers or, more specifically, one of ordinary skill would find it obvious to use compounds that are effective for non-metastatic gastric cancer as treatment for metastatic gastric cancer. Vishnudas teaches compound 126 and contemplates methods of treating gastric cancer. NCI teaches treatment for metastatic gastric cancer would be the same as non-metastatic gastric cancer. Therefore, it would have been prima facie obvious at the time of the effective filing date for one of ordinary skill in the art to take compound 126 and use it to treat gastric cancer and metastatic gastric cancer with a reasonable assumption of success. One of ordinary skill in the art would find motivation to use the compound as Vishnudas contemplates treatment for gastric cancer using compound 126. Response to Arguments Applicant's arguments filed 09/14/2026 have been fully considered but they are not persuasive. Applicant states “In order to establish a prima facie case of obvious, one of skill in the art reading the prior art, must be motivated to combine the prior art in a manner which would lead to the claim invention…simply because the claimed features are ‘known’, that is not enough to satisfy a motivation to combined.” Applicant points to Virtek Vision International ULC v. Assembly Guidance Systems Inc., 97 F.4th 882 and cites the court stating “[it] does not suffice [for two alternative arrangements] to simply be known. A reason for combining must exist” and “this case involves nothing other than an assertion that because two coordinate system were disclosed in a prior art reference and were therefore ‘known,’ that satisfies the motivation to combine analysis. That is an error as a matter of law. It does not suffice to simply be known. A reason for combining must exist.” Applicant concludes that “Here, no such motivation exists.” Applicant points to Vishnudas and states that the reference “is directed to chemical compounds which are taught as being useful for treating conditions associated with modulation of UBE2K.” Applicant argues that one of ordinary skill in the art would be required to elect one compound out of 140 compounds disclosed in Vishnudas and then “arbitrarily” elect gastrointestinal cancer and/or metastatic gastrointestinal cancer. Applicant argues that “there is no data or evidence in Vishnudas that would have compelled one of skill in the art to arrive at specifically treating gastric cancer using the single compound as claimed. NCI fails to cure this deficiency.” Applicant then argues that the combination of Vishnudas and NCI would not lead to a reasonable expectation of success and states that “when dealing with technology surrounding the chemical arts…there is a heightened burden on the Office to justify whether a claimed invention would have been predictable.” Applicant also states “ ‘[t]o the extent an art is unpredictable, as the chemical arts often are, KSR’s focus on these ‘identified, predictable solutions’ may present a difficult hurdle because potential solutions are less likely to be genuinely predictable.” Regarding the gastrointestinal cancer, applicant states “gastrointestinal cancer is one of many cancers described in Vishnudas. Yet, all the biological data in Vishnudas is directed to leukemia. Gastrointestinal cancer and leukemia are completely different tumor types, Leukemia is a liquid blood cancer that states in the bone marrow, while gastrointestinal (GI) cancer is a solid tumor that forms in the digestive tract. Therefore [there] is no expectation that [an] agent that is useful for treating gastrointestinal cancer would also be useful for treating leukemia, and vice versa.” The arguments regarding the combination of Vishnudas and NCI are not persuasive because the combination is not combining two separate components that are known within the art. Vishnudas contemplates gastrointestinal cancer, a genus, and NCI teaches that metastatic cancers, a species within the genus of gastrointestinal cancer, are treated using the same medication that is used for the parent cancer. NCI is used to show that the application of Vishnudas would also apply to metastatic cancers. Regarding predictability, applicant has simply stated that there is unpredictability without explaining where unpredictability lies. Vishnudas teaches that the compounds of its invention are “useful for treating conditions associated with modulation of UBE2K”, which then connects to cancers (col. 8, l. 12-13), and, further, gastrointestinal cancer (col. 8, l. 35). Compound 126’s efficacy as a UBE2K modulator is taught in col. 125, Table 11 and in Fig. 3. Compound 126 also stands out as 1 of 5 compounds tested (Fig. 1-3) and one of 2 compounds tested for tumor inhibition (col. 126, Table 11). Additionally, Vishnuda claims compound 126 in reference claims 1, 2, 4, and 6. One of ordinary skill would be inclined to elect compound 126 as it is 1 of 3 compounds claimed. Essentially, one of ordinary skill would see compound 126 as a preferred embodiment. Further, the listing of cancers in col. 8, l. 30-35 listed 5 cancers. Similar to the election of compound 126, one of ordinary skill would be inclined to apply the compound 126 to any of the 5 listed cancers which includes gastrointestinal cancer via KSR E. Essentially, one of ordinary skill could elect compound 126 and then administer it to treat gastrointestinal cancer as it would be obvious to try. Therefore, its election would not be arbitrary and its application as a UBE2K modulator to inhibit a cancer associated with UBE2K (including gastrointestinal cancer) would be predictable. Conclusion No claims allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUISALBERTO GONZALEZ whose telephone number is (571)272-1154. The examiner can normally be reached M-F 8:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /L.G./Examiner, Art Unit 1624 /JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 17, 2024
Application Filed
May 14, 2026
Non-Final Rejection mailed — §103
Sep 14, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760058
PRODRUGS OF NEUROACTIVE STEROIDS
4y 1m to grant Granted Oct 13, 2026
Patent 12708620
PRODRUGS AND MEDICAL USES THEREOF
5y 8m to grant Granted Aug 18, 2026
Patent 12708622
METHODS OF TREATING CANCER AND INHIBITING TYK2 AND MEK
3y 9m to grant Granted Aug 18, 2026
Patent 12698271
CRYSTALLINE FORM OF A SHP2 INHIBITOR
2y 10m to grant Granted Aug 04, 2026
Patent 12662481
SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
4y 5m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+48.3%)
Moderate
PTA Risk
Based on 164 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month